On 8/9/24, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock suffered a major decline of -10.6%, closing at $6.61. Moreover, exceptionally high trading volume at 436% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 4.9% during the last week.
Current PriceTarget Research Rating
ZVRA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Zevra Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Zevra Therapeutics has a poor Power Rating of 29 and a very low Appreciation Score of 2, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment